FY2019 EPS Estimates for Cellectis SA (CLLS) Lowered by Jefferies Financial Group
Cellectis SA (NASDAQ:CLLS) – Analysts at Jefferies Financial Group dropped their FY2019 earnings per share (EPS) estimates for Cellectis in a research note issued to investors on Wednesday, March 13th. Jefferies Financial Group analyst B. Amin now expects that the biotechnology company will post earnings of ($2.90) per share for the year, down from their previous forecast of ($1.23). Jefferies Financial Group also issued estimates for Cellectis’ Q4 2019 earnings at ($0.78) EPS, FY2020 earnings at ($1.42) EPS, FY2021 earnings at $1.20 EPS and FY2022 earnings at $2.29 EPS.
A number of other equities research analysts have also recently weighed in on CLLS. BidaskClub cut shares of Cellectis from a “sell” rating to a “strong sell” rating in a research report on Wednesday, November 21st. Oppenheimer set a $44.00 price target on shares of Cellectis and gave the company a “buy” rating in a research report on Sunday, November 25th. Goldman Sachs Group initiated coverage on shares of Cellectis in a research report on Wednesday, December 19th. They issued a “neutral” rating and a $25.00 price target for the company. Zacks Investment Research raised shares of Cellectis from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Thursday, January 3rd. Finally, ValuEngine cut shares of Cellectis from a “hold” rating to a “sell” rating in a research report on Thursday, January 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $32.00.
Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.14. Cellectis had a negative net margin of 362.48% and a negative return on equity of 18.63%. The firm had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $7.46 million.
Large investors have recently made changes to their positions in the company. Financial Gravity Companies Inc. purchased a new stake in shares of Cellectis in the fourth quarter valued at about $71,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in shares of Cellectis by 37.6% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,545 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 1,787 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Cellectis in the fourth quarter valued at about $180,000. KBC Group NV raised its holdings in shares of Cellectis by 22.9% in the fourth quarter. KBC Group NV now owns 14,266 shares of the biotechnology company’s stock valued at $238,000 after buying an additional 2,661 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in shares of Cellectis by 28.3% in the fourth quarter. Squarepoint Ops LLC now owns 16,455 shares of the biotechnology company’s stock valued at $274,000 after buying an additional 3,626 shares during the last quarter. 27.61% of the stock is owned by institutional investors and hedge funds.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Featured Article: Limitations of the P/E Growth ratio
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.